{"id":"NCT01665144","sponsor":"Novartis Pharmaceuticals","briefTitle":"Exploring the Efficacy and Safety of Siponimod in Patients With Secondary Progressive Multiple Sclerosis (EXPAND)","officialTitle":"A Multicenter, Randomized, Double-blind, Parallel-group, Placebo-controlled Variable Treatment Duration Study Evaluating the Efficacy and Safety of Siponimod (BAF312) in Patients With Secondary Progressive Multiple Sclerosis Followed by Extended Treatment With Open-label BAF312.","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2012-12-20","primaryCompletion":"2016-04-29","completion":"2023-03-31","firstPosted":"2012-08-15","resultsPosted":"2018-10-31","lastUpdate":"2024-06-05"},"enrollment":1651,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"DOUBLE","primaryPurpose":"TREATMENT"},"conditions":["Secondary Progressive Multiple Sclerosis"],"interventions":[{"type":"DRUG","name":"BAF312","otherNames":[]},{"type":"DRUG","name":"Placebo","otherNames":[]}],"arms":[{"label":"Siponimod (BAF312)","type":"EXPERIMENTAL"},{"label":"Placebo","type":"PLACEBO_COMPARATOR"}],"summary":"Evaluate the safety and efficacy of Siponimod (BAF312) versus placebo in a variable treatment duration in patients with secondary progressive multiple sclerosis (Core Part) followed by extended treatment with open-label BAF312 to obtain data on long-term safety, tolerability and efficacy (Extension Part).","primaryOutcome":{"measure":"Percentage of Participants With 3-month Confirmed Disability Progression (CDP) Events as Measured by the Expanded Disability Status Scale (EDSS)","timeFrame":"Baseline, every 3 month up to the maximum of approximately 3 years","effectByArm":[{"arm":"Siponimod (BAF312)","deltaMin":26.3,"sd":null},{"arm":"Placebo","deltaMin":31.7,"sd":null}],"pValues":[{"comp":"OG000 vs OG001","p":"0.0134"}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":4,"exclusionCount":5},"locations":{"siteCount":290,"countries":["United States","Argentina","Australia","Austria","Belgium","Bulgaria","Canada","China","Czechia","Estonia","France","Germany","Greece","Hungary","Ireland","Israel","Italy","Japan","Latvia","Lithuania","Netherlands","Poland","Portugal","Romania","Russia","Slovakia","Spain","Sweden","Switzerland","Turkey (TÃ¼rkiye)","United Kingdom"]},"refs":{"pmids":["35639197","35380078","35379762","35261318","33791945","33328324","29576505"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":196,"n":1099},"commonTop":["Urinary tract infection","Nasopharyngitis","Fall","Headache","Hypertension"]}}